新一代治疗阿尔茨海默病的胆碱酯酶抑制剂多奈哌齐  

DONEPEZIL——A NEW GENERATION OF CHOLINESTERASE INHIBITOR FOR ALZHEIMER'S DISEASE

作　　者：程勇[1] 宋友华[1] 傅得兴[1] 

机构地区：[1]卫生部北京医院,北京100730

出　　处：《中国新药杂志》2000年第5期300-303,共4页Chinese Journal of New Drugs

摘　　要：多奈哌齐是六氢哌啶衍生物 ,为可逆性乙酰胆碱酯酶抑制剂 ,对胆碱酯酶有极高的选择性。对轻 中度阿尔茨海默病患者的临床症状有较好的改善作用 ,临床试验尚未发现与其他药物有相互干扰作用。该药半衰期长 ,不良反应轻微 。Donepezil, a hexahydropiperidine derivative, is a reversible acetylcholinesterase inhibitor which is highly selective for cholinesterase.It is effective in improving symptom of mild to moderate Alzheimer' disease.No drug interactions were observed in clinical trial.Donepezil is a drug with long half life and low incidence of adverse effects but without hepatoxicity.

关 键 词：多奈哌齐 乙酰胆碱酯酶抑制剂 药理 老年性痴呆 

分 类 号：R971.9[医药卫生—药品]